CN114401725A - 用于在左旋多巴诱发的运动障碍的预防性和/或治疗性治疗中使用的药物组合物 - Google Patents

用于在左旋多巴诱发的运动障碍的预防性和/或治疗性治疗中使用的药物组合物 Download PDF

Info

Publication number
CN114401725A
CN114401725A CN202080053643.6A CN202080053643A CN114401725A CN 114401725 A CN114401725 A CN 114401725A CN 202080053643 A CN202080053643 A CN 202080053643A CN 114401725 A CN114401725 A CN 114401725A
Authority
CN
China
Prior art keywords
levodopa
pharmaceutical composition
fasudil
dyskinesia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080053643.6A
Other languages
English (en)
Chinese (zh)
Inventor
帕蒂诺 A·M·穆尼奥斯
加西亚 J·L·拉班德拉
罗佩斯 A·罗佩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Publication of CN114401725A publication Critical patent/CN114401725A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080053643.6A 2019-07-31 2020-07-24 用于在左旋多巴诱发的运动障碍的预防性和/或治疗性治疗中使用的药物组合物 Pending CN114401725A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201930713A ES2804076B2 (es) 2019-07-31 2019-07-31 Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa
ESP201930713 2019-07-31
PCT/ES2020/070482 WO2021019116A1 (es) 2019-07-31 2020-07-24 Composición farmacéutica para su uso en el tratamiento profiláctico y/o terapéutico de discinesias inducidas por l-dopa

Publications (1)

Publication Number Publication Date
CN114401725A true CN114401725A (zh) 2022-04-26

Family

ID=74229008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053643.6A Pending CN114401725A (zh) 2019-07-31 2020-07-24 用于在左旋多巴诱发的运动障碍的预防性和/或治疗性治疗中使用的药物组合物

Country Status (8)

Country Link
US (2) US11337985B2 (https=)
EP (1) EP4005574B1 (https=)
JP (2) JP7780420B2 (https=)
KR (1) KR20220050905A (https=)
CN (1) CN114401725A (https=)
CA (1) CA3145360A1 (https=)
ES (2) ES2804076B2 (https=)
WO (1) WO2021019116A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804076B2 (es) * 2019-07-31 2021-07-12 Univ Santiago Compostela Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804076B2 (es) * 2019-07-31 2021-07-12 Univ Santiago Compostela Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa

Also Published As

Publication number Publication date
JP7780420B2 (ja) 2025-12-04
JP2025169440A (ja) 2025-11-12
EP4005574C0 (en) 2024-07-03
US20220211719A1 (en) 2022-07-07
US11337985B2 (en) 2022-05-24
ES2804076A1 (es) 2021-02-03
KR20220050905A (ko) 2022-04-25
WO2021019116A1 (es) 2021-02-04
CA3145360A1 (en) 2021-02-04
ES2804076B2 (es) 2021-07-12
JP2022542305A (ja) 2022-09-30
EP4005574A4 (en) 2023-05-24
ES2987334T3 (es) 2024-11-14
US12465613B2 (en) 2025-11-11
EP4005574B1 (en) 2024-07-03
US20210393646A1 (en) 2021-12-23
EP4005574A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
Gardoni et al. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias
Bordia et al. Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson’s disease
Levandis et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
EP2601964B1 (en) Balanol compounds for use in treating pain
Decressac et al. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats
Potts et al. Dual κ‐agonist/μ‐antagonist opioid receptor modulation reduces levodopa‐induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of P arkinson disease
Weber et al. cGMP-dependent protein kinase inhibitor blocks light-induced phase advances of circadian rhythms in vivo
Lebel et al. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat
Stanic et al. Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias
Gou et al. Pharmacology and mechanism of action of HSK16149, a selective ligand of α2δ subunit of voltage-gated calcium channel with analgesic activity in animal models of chronic pain
Pagano et al. PET molecular imaging research of levodopa-induced dyskinesias in Parkinson’s disease
Fuzzati‐Armentero et al. Dual target strategy: combining distinct non‐dopaminergic treatments reduces neuronal cell loss and synergistically modulates L‐DOPA‐induced rotational behavior in a rodent model of Parkinson's disease
Sasaki et al. Evaluation of canthinone alkaloids as cerebral protective agents
JP2025169440A (ja) Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物
Alves et al. NO/cGMP production is important for the endogenous peripheral control of hyperalgesia during inflammation
Kotagale et al. Agmatine prevents development of tolerance to anti-nociceptive effect of ethanol in mice
Lenda et al. Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
Ye et al. Anesthetic effects on autophagy
US6489356B2 (en) Method for treating pain in humans
Jonkers et al. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats
Damaj Calcium-acting drugs modulate expression and development of chronic tolerance to nicotine-induced antinociception in mice
Papathanou et al. The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats
Stocchi Dopamine receptor agonists in the treatment of advanced Parkinson's disease
Romero-Alejo et al. Inhibition of astrocyte activation is involved in the prevention of postoperative latent pain sensitization by ketamine and gabapentin in mice
Lee et al. Roles of adenosine receptor subtypes on the antinociceptive effect of sildenafil in rat spinal cord

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination